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urrently, in County 2 we have vaccinated 10.5% of students
70 out of 663). For the current inﬂuenza season, students
n County 1 are almost 200% more likely to get vaccinated
han students in County 2 (RR = 2.88, 95% CI: 2.20-3.77).
Conclusion: We have observed a greater percentage of
tudents vaccinated in the school-based intervention than
n the provider-based intervention during the previous and
urrent inﬂuenza seasons (p = 0.0912 and p < 0.0001, respec-
ively). This study has implications for best practices for
ass campaigns during an inﬂuenza pandemic, such as the
urrent H1N1 inﬂuenza pandemic. This study is funded by
DC 5 R18 IP000166.
oi:10.1016/j.ijid.2010.02.2200
5.003
randomized intervention trial of mask use and hand
ygiene to reduce seasonal inﬂuenza-like illness and
nﬂuenza infections among young adults in a university
etting
.E. Aiello1,∗, R.M. Coulborn1, V. Perez1, B.M. Davis1, M.
ddin1, G.F. Murray2, D.K. Shay3, S.H. Waterman3, A.S.
onto1
University of Michigan School of Public Health, Ann Arbor,
I, USA
University of South Alabama, Mobile, AL, USA
Centers for Disease Control and Prevention, Atlanta, GA,
SA
Background: Early efforts to decrease transmission of
andemic inﬂuenza will likely rely on nonpharmaceuti-
al interventions (NPIs), because of delays in availability
f suitable vaccines and limited stock of antiviral med-
cations. We conducted a randomized trial to estimate
eductions in inﬂuenza-like illness (ILI) and laboratory-
onﬁrmed inﬂuenza infection associated with use of face
asks combined with hand hygienemeasures and facemasks
lone in a university setting.
Methods: During the 2007-08 inﬂuenza season, 1,111
tudents residing in university residence halls were cluster-
andomized by residence house (N = 37) to either face mask
nd hand hygiene, face mask only, or control arms. Discrete-
ime survival analysis using generalized models estimated
ate ratios, according to study arm, each week and cumu-
atively over the 6-week intervention period, for clinically
eriﬁed ILI and laboratory-conﬁrmed inﬂuenza A or B.
Results: In the mask and hand hygiene group com-
ared with the control group, adjusting for covariates, we
bserved signiﬁcant reductions in ILI incidence during weeks
(RR, 52%, [95% CI, 6%-76%]) and 5 (RR, 62%, [CI, 6%-85%]),
nd a borderline signiﬁcant reduction during week 6 (RR,
0%, [CI, 2%-91%]). For laboratory-conﬁrmed inﬂuenza, both
he face mask only and the face mask and hand hygiene
roups compared to the control showed a reduction in cumu-
ative incidence, however results did not reach statistical
igniﬁcance; polymerase chain reaction (PCR) conﬁrmed
nﬂuenza A or B in 11 out of 49 samples (22%) in the face
ask and hand hygiene group, 16 out of 58 samples (28%) in
he face mask only group, and 18 out of 68 samples (26%) in
he control group.
w
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Conclusion: These ﬁndings suggest that in shared living
nvironments, the use of face masks and hand hygiene may
educe inﬂuenza-like illnesses.
Trial registration: www.clinicaltrials.gov, Identiﬁer:
CT00490633
oi:10.1016/j.ijid.2010.02.2201
5.004
opulation-based surveillance for 2009 pandemic
nﬂuenza A H1N1 Virus in Guatemala, 2009
. Arvelo1,∗, L. Reyes2, A. Estevez3, J. Gray3, S.
indstrom1, A. Fry1, S. Olsen1, F. Ardon2, G. Frenkel3, B.
ordillo2, K. Lindblade1
Centers for Disease Control and Prevention, Atlanta, GA,
SA
Ministry of Public Health and Social Assistance, Guatemala
ity, Guatemala
Universidad del Valle de Guatemala, Guatemala City,
uatemala
Background: Worldwide >414,000 cases of pandemic
nﬂuenza H1N1 2009 (2009 H1N1) and nearly 5000 deaths
ave been reported. The 2009 H1N1 was ﬁrst identiﬁed in
exico in April 2009, but spread into neighboring Guatemala
ccurred weeks later. We describe the clinical and epidemi-
logic characteristics of patients with 2009 H1N1 infection
n two sites in Guatemala.
Methods: We analyzed data from an active population-
ased surveillance for clinical pneumonia and inﬂuenza-like
llnesses (ILI) in hospitals and ambulatory clinics, respec-
ively, in the departments of Santa Rosa and Quetzaltenango
n Guatemala from February through September 2009. Clin-
cal and epidemiological information, and nasopharyngeal
wabs were collected from enrolled patients. Specimens
ere tested for inﬂuenza with real-time reverse transcrip-
ase polymerase chain reaction.
Results: We identiﬁed 198 persons with 2009 H1N1 infec-
ion between May and September 2009; 61 (31%) were
ospitalized with pneumonia and six died (case fatality pro-
ortion: 2.7%, 95% conﬁdence interval 0.9%-6.3%). Among
nﬂuenza cases identiﬁed between February and May, the
roportion caused by 2009 H1N1 rose from 0% in February
o 67% in May. By July in any given week 80% to 100% of
nﬂuenza A viruses were 2009 H1N1. The median age of per-
ons with 2009 H1N1 infection was nine years, and among
atients hospitalized with pneumonia six years. Fever >38 ◦C
as documented in 37 (60%) pneumonia patients, 53 (85%)
ersons self-reported fever. Adjusted hospitalization rates
ere highest for children <5 years old (154.9 per 100,000) in
anta Rosa. Fourteen (23%) hospitalized patients with 2009
1N1 were admitted to the intensive care unit (ICU) and
ve (8%) requiredmechanical ventilation. Among children <5
ears, nine (28%) were admitted to the ICU and three (10%)
ied. Underlying chronic conditions were noted in <20% of
atients hospitalized with 2009 H1N1 infection.
Conclusion: Although seasonal inﬂuenza A (H1N1/H3N2)
as circulating prior to widespread 2009 H1N1 transmis-
ion, it was quickly replaced by the 2009 H1N1 virus. The
pidemiology was similar to reports elsewhere except for
he low frequency of underlying disease among hospitalized
trac
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patients. Surveillance for H1N1 requiring documented fever
will underestimate burden of disease. Children <5 years old
in Guatemala should be prioritized for vaccination.
doi:10.1016/j.ijid.2010.02.2202
65.005
Adjuvanted inﬂuenza vaccines and their potential role for
vaccination of travelers
T. Tsai 1,∗, N. Groth2, M. Pellegrini 2, D. O’Hagan1, A.
Hilbert3
1 Novartis Vaccines and Diagnostics, Cambridge, MA, USA
2 Novartis Vaccines and Diagnostics, Sienna, Italy
3 Novartis Vaccines and Diagnostics, Marburg, Germany
Background: Trivalent seasonal inﬂuenza vaccine (TIV)
adjuvanted with the emulsion adjuvant MF59® (FLUAD®)
is licensed in 29 countries worldwide for adults over 65
years of age. Compared with unadjuvanted TIV, the adju-
vanted vaccine provides higher hemagglutination inhibition
(HI) antibody titers not only against vaccine strains, but also
against drift-variant strains. Usually inﬂuenza is transmitted
in a single epidemic seasonal epidemic in temperate cli-
mates, but it may appear in two epidemics during the year
or may be transmitted throughout the year, in subtropical
and tropical locations. Although persons travelling from the
Northern Hemisphere (NH) to the tropics or antipodes may
not have access to the TIV made with strains used in the
Southern Hemisphere (SH) formulation, they are neverthe-
less recommended to receive available NH formulation-TIV
because one or more of the strains may overlap and because
some degree of protection may be elicited, even by an
imperfectly matched vaccine.
Methods: The following data from recent clinical
trials highlight the cross-protection elicited by the MF59-
adjuvanted vaccine. Sera from 222 children, 6-36 months of
age, vaccinated with the 2006/07 formulations of FLUAD or
unadjuvanted TIV were tested against the H1N1 strain in the
2007/08 formulation (A/Solomon Islands/3/2006 (H1N1)-
like). Sera from adults with chronic illnesses and elderly
adults (> 65 years) were similarly tested.
Results: In the children geometric mean titer (GMT) HI
responses, geometric mean ratios (GMR), and seroprotec-
tion (SP) rates were signiﬁcantly higher in FLUAD recipients.
Similar signiﬁcant differences were seen among 349 adults
with chronic illnesses with increased risk for inﬂuenza mor-
bidity who were vaccinated with either FLUAD or with an
undajuvanted subunit vaccine. Finally, 56 elderly adults who
received the 2007/08 FLUAD formulation displayed postvac-
cination responses against strains in the 2008/09 formulation
which met the European Committee for Human Medicinal
Products criteria for GMR, SP and SC for the mismatched
H1N1 and H3N2 strains.
Conclusion: Altogether these results suggest that the
greater degree of cross-variant immunity elicited by MF59-
adjuvanted inﬂuenza vaccine may offer an advantage in
circumstances where travelers may be exposed to antigeni-
cally mismatched viruses.
doi:10.1016/j.ijid.2010.02.2203
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easonal inﬂuenza vaccine may be associated with
ncreased risk of illness due to the 2009 pandemic A/H1N1
irus
.M. Skowronski 1,∗, G. De Serres2, N. Crowcroft3, N.
anjua1, N. Boulianne2, T.S. Hottes1, L.C. Rosella3, J.A.
ickinson4, G. Rodica2, P. Sethi 3, N. Ouhoummane2,
.J. Willison3, I. Rouleau2, K. Fonseca5, S.J. Drews6, A.
ebbapragada3, H. Charest7, M.-E. Hamelin7, G. Boivin7,
. Gardy1, Y. Li 8, P. Martin1
BC Centre for Disease Control, Vancouver, BC, Canada
Institut national de santé publique du Québec, Québec,
C, Canada
Ontario Agency for Health Protection and Promotion,
oronto, ON, Canada
University of Calgary, Alberta, AB, Canada
Alberta Provincial Laboratory, Calgary, AB, Canada
University of Calgary, Calgary, AB, Canada
CHUQ research Center, Laval University, Canada, Quebec,
C, Canada
National Microbiology Laboratory, Public Health Agency of
anada, Winipeg, MB, Canada
Background: In late spring 2009, concern was raised in
anada that prior receipt of the 2008-09 trivalent inacti-
ated inﬂuenza vaccine (TIV) was associated with increased
isk of pandemic H1N1 (pH1N1) illness. Several epidemio-
ogic investigations were urgently conducted through the
ummer to assess this putative association.
Methods: Studies included: (1) test-negative case-control
esign based on Canada’s ongoing sentinel vaccine effective-
ess monitoring system in British Columbia, Alberta, Ontario
nd Quebec; (2) conventional case-control design using pop-
lation controls in Quebec; (3) testnegative case-control
esign in Ontario and (4) prospective household transmis-
ion (cohort) study in Quebec. Logistic regression estimated
dds ratios for TIV effect on community- or hospital-based
aboratory-conﬁrmed seasonal or pH1N1 inﬂuenza cases
ompared to controls with restriction, stratiﬁcation and
djustment for covariates including combinations of age,
ex, comorbidity, timeliness of medical visit, prior physician
isits, and/or health care worker status. For the prospective
tudy relative risks were computed.
Results: Based on the sentinel study of ∼700 cases and
00 controls, 2008-09 TIV provided statistically signiﬁcant
rotection against seasonal inﬂuenza (OR 0.44;95% CI 0.33-
.59). Conversely, estimates from the sentinel and several
ther study designs involving ∼1200 laboratory-conﬁrmed
H1N1 cases and 1500 controls consistently showed that
rior recipients of 2008-09 TIV were at statistically sig-
iﬁcant 1.5-2.5-fold increased risk of medically-attended
H1N1 illness during the spring/summer 2009 with upper
imit of the 95% conﬁdence interval spanning 3-4-fold
ncrease. There was non-signiﬁcant increase in the strength
f the association with more TIV doses received in the prior
ve years. Risk of pH1N1 hospitalization was not further
ncreased among vaccinated people when comparing hos-
italized to community cases.
Conclusion: Prior receipt of 2008-09 TIV was associ-
ted with increased risk of medicallyattended pH1N1 illness
uring the spring/summer 2009 in Canada. Possible biologi-
